Back to Search
Start Over
Demystifying biosimilars: development, regulation and clinical use
- Publication Year :
- 2019
- Publisher :
- FUTURE MEDICINE LTD, 2019.
-
Abstract
- Biologics are an integral component in the treatment of various diseases. However, limited patient access to these medicines remains a significant global challenge, prompting development of safe and effective biosimilars. A biosimilar is 'highly similar to a reference (originator) product, for which there are no clinically meaningful differences between the two products in terms of safety, purity and potency'. Biosimilars have the potential to offer possible benefits, including lower treatment costs, thereby increasing patient access and clinical use, which may lead to better overall outcomes. Improved understanding of biosimilars may enhance confidence and trust in these agents. As increasing numbers of biosimilars achieve regulatory approval, this overview aims to address enduring knowledge gaps regarding the development and use of biosimilars. ispartof: FUTURE ONCOLOGY vol:15 issue:7 pages:777-790 ispartof: location:England status: published
- Subjects :
- 0301 basic medicine
Cancer Research
extrapolation
Guidelines as Topic
myths
03 medical and health sciences
0302 clinical medicine
Drug Development
Humans
Medicine
Treatment costs
Biosimilar Pharmaceuticals
Drug Approval
development
Clinical Trials as Topic
Drug Substitution
business.industry
Biosimilar
General Medicine
030104 developmental biology
Therapeutic Equivalency
Oncology
Risk analysis (engineering)
regulatory approval
030220 oncology & carcinogenesis
Government Regulation
biosimilar
business
interchangeability
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....a961113355177163859d5f774b6c7cbd